Men with hormone-resistant prostate cancer and specific genetic mutations who were treated with the PARP inhibitor drug olaparib survived longer than men treated with traditional hormone therapy, according to an analysis ...
Dec 7, 2023
0
1
The results from the major phase III OlympiA trial shows the drug improves survival rates in women who have inherited faults in their BRCA1 or BRCA2 genes.
Mar 17, 2022
0
23
(HealthDay)—One year of adjuvant olaparib should be offered to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant ...
Jul 9, 2021
0
2
Results were released this week on a new treatment with the potential to improve the outcomes for patients with hereditary BRCA mutations and high-risk, early-stage breast cancer. These results represent the first time a ...
Jun 4, 2021
0
8
Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years, a new study shows.
Sep 21, 2020
0
3
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.
Sep 20, 2020
0
101
Australian researchers have shown for the first time that a new drug used to treat breast cancer patients damages the store of immature eggs in the ovaries of mice.
Jul 1, 2020
0
55
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.
Apr 28, 2020
0
178
(HealthDay)—Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with advanced ovarian cancer, according ...
Dec 19, 2019
0
0
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.
Dec 3, 2019
0
2
